Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Status Recruiting

Clinical Trial Summary

This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients.

Clinical Trial Description

Breast cancer is the most frequent malignancy in women worldwide. Treatments on metastatic HER2 negative breast cancer are still under exploration. Therefore, it is imperative to find a novel therapy to treat these patients. This study explores the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients. The primary objective is to evaluate the progression free survival (PFS). The secondary objective is to evaluate the safety of the combination of eribulin and anlotinib. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04624711
Study type	Interventional
Source	The First Affiliated Hospital with Nanjing Medical University
Contact	Yongmei Yin
Phone	13951842727
Email	ymyin@njmu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	March 1, 2021
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Completed	`NCT02371174` - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.
Completed	`NCT02225470` - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Phase 3
Recruiting	`NCT05173103` - Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
Active, not recruiting	`NCT04448886` - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Phase 2
Not yet recruiting	`NCT04498793` - Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer	Phase 2
Completed	`NCT01705691` - Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer	Phase 2
Terminated	`NCT01368263` - Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer	Phase 2
Recruiting	`NCT04576143` - Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer	Phase 2/Phase 3
Completed	`NCT05054374` - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05467891` - Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	Phase 2
Recruiting	`NCT04660435` - To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Completed	`NCT02015559` - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus	Phase 2
Completed	`NCT04504916` - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)	Phase 2
Terminated	`NCT04738292` - Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)	Phase 2
Recruiting	`NCT05982093` - Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer	Phase 2
Recruiting	`NCT05396612` - Role of the Immune Environment in Response to Therapy in Breast Cancer
Active, not recruiting	`NCT04595565` - Sacituzumab Govitecan in Primary HER2-negative Breast Cancer	Phase 3
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Terminated	`NCT01234532` - Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery	Phase 2